Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aridis Pharmaceuticals Inc (ARDS)

Aridis Pharmaceuticals Inc (ARDS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 11
  • Shares Outstanding, K 53,321
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -30,370 K
  • EBIT $ -1 M
  • EBITDA $ 0 M
  • 60-Month Beta 1.02
  • Price/Sales 0.00
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.02 on 11/06/23
  • Next Earnings Date 11/04/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 +200.00%
on 10/25/24
0.0003 unch
on 11/04/24
+0.0002 (+200.00%)
since 07/31/24
3-Month
0.0001 +200.00%
on 10/25/24
0.0003 unch
on 11/04/24
-0.0007 (-70.00%)
since 07/19/24
52-Week
0.0001 +200.00%
on 10/25/24
0.0960 -99.69%
on 11/07/23
-0.0922 (-99.68%)
since 11/03/23

Most Recent Stories

More News
FDA Provides Positive Feedback for Aridis Pharmaceuticals’ (NASDAQ: ARDS) AR-301 Phase 3 Study

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) receives encouraging input from the FDA for the proposed confirmatory Phase 3 trial of AR-301,

ARDS : 0.0002 (unch)
Biotech Pops On New Patient Enrollment Announcement

A California-based %Biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a...

ARDS : 0.0002 (unch)
Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced today that patient enrollment is closed in the AR-301 Phase 3 clinical study. The Company...

ARDS : 0.0002 (unch)
Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...

ARDS : 0.0002 (unch)
Pre-Market Brief: Stocks Rebound After Steep Losses

December S&P 500 futures (ESZ22) are trending higher +1.11% this morning after three major US benchmark indices extended declines for the 5th consecutive session as investors continue to fret that higher...

ESZ22 : 3,871.47s (-0.66%)
NEXI.M.DX : 5.744 (-1.17%)
MARA : 15.81 (-1.86%)
HUT : 15.80 (-1.37%)
RIOT : 9.15 (-3.07%)
NMTR : 0.0722 (-42.97%)
ARDS : 0.0002 (unch)
NVDA : 138.13 (+2.02%)
NLS : 0.8204 (+11.20%)
KDP : 32.76 (-0.18%)
SNAP : 12.16 (-2.95%)
Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...

ARDS : 0.0002 (unch)
Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...

ARDS : 0.0002 (unch)
RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong

ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July...

ARDS : 0.0002 (unch)
Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)

Kermode Biotechnologies, Inc., a privately-held US-based biotechnology company focused on animal health, announced that it is actively engaged in discovery to identify the mode of transmission and replication...

ARDS : 0.0002 (unch)
CORRECTING and REPLACING Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)

Email address in contact of release should read: kiran@mkainsights.com .

ARDS : 0.0002 (unch)

Business Summary

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are...

See More

Key Turning Points

3rd Resistance Point 0.0004
2nd Resistance Point 0.0003
1st Resistance Point 0.0003
Last Price 0.0002
1st Support Level 0.0002
2nd Support Level 0.0001
3rd Support Level 0.0001

See More

52-Week High 0.0960
Fibonacci 61.8% 0.0594
Fibonacci 50% 0.0481
Fibonacci 38.2% 0.0367
Last Price 0.0002
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar